摘要:
In a process for drying microporous, fluid-containing particles, the fluid-containing particles to be dried are fed as a moving bed countercurrently to a drying fluid, the interfacial tension of the fluid being reduced in comparison with the interfacial tension of the fluid at room temperature, at near-critical to supercritical pressure of the fluid, preferably to a value in the range from 0 to {fraction (1/10)}, in particular from 0 to {fraction (1/20)}, of the interfacial tension at room temperature. Furthermore, microporous, three-dimensionally networked particles are prepared by a process comprising preparation of microporous particles containing pore liquid, exchange of the pore liquid in the particles for a fluid and drying of the fluid-containing particles, the exchange and drying being carried out in the moving bed by the countercurrent method.
摘要:
In a process for drying microporous, fluid-containing particles, the heat required for increasing the temperature is supplied by convection by reducing the interfacial tension of the fluid, preferably to 0 to 1/10, in particular to 0 to 1/20, of the interfacial tension of the fluid at room temperature, by appropriately increasing the temperature at from close to the critical pressure to supercritical pressure of the fluid. Furthermore, microporous, three-dimensionally networked particles are prepared by a process in which the drying process is used. In addition, an apparatus is used for carrying out the drying process, the apparatus comprising a pressure container having an inner container and pressure-withstanding outer container and suitable measuring and control apparatuses and pump apparatuses and heat exchangers, the inner container being provided for holding the particles to be dried and a gap being provided between the inner container and the outer container.
摘要:
Provided is a method of treating or ameliorating a number of indications in an animal, including a human, comprising administering an effective amount of a compound of the formula I or IA, wherein J is oxygen, sulfur, or N—Rd.
摘要:
A memory having an array of memory cells. The array includes a plurality of normal memory cells and a redundant memory cell. A decoder is provided for selecting an addressed one of the normal memory cells in response to an address and a normal condition signal and adapted address the redundant memory cell in response to the address and a fault condition signal. A redundant decoder is provided having an electronically erasable read-only-memory cell. The redundant decoder is adapted to produce the normal condition signal and to convert the normal condition signal into the fault condition signal when such read-only-memory cell is programmed into a fault condition. Each one of the read-only memory cells include a flash memory cell, a ferroelectric memory cell, or other such type of electronically erasable read-only memory cell which is substantially non-volatile and is able to retain its programmed state for a relatively long period of time. With such an arrangement, because the electronically erasable read-only-memory cell is electronically programmable, a defective normal memory cell may be replaced with a redundant memory cell the memory is packaged.
摘要:
The present invention provides certain substituted-piperazinyl-1,2,4-triazoles which are useful for the treatment of sensitized humans for allergies and anaphylactic reactions.
摘要:
3-Substituted 4-(.alpha.-amino-.alpha.-phenyl-o-tolyl)-4H-1,2,4-triazoles, 2-substituted 1-(.alpha.amino-.alpha.-phenyl-o-tolyl)imidazoles, pharmacologically acceptable acid addition salts thereof and processes for their production. The compounds of this invention and the pharmacologically acceptable acid addition salts thereof are useful as sedatives, hypnotics, anticonvulsants, tranquilizers, and muscle relaxants. They are also useful as feed additives for increasing growth rate and feed efficiency of livestock and poultry.
摘要:
Compounds of the formula I: ##STR1## wherein R.sub.1 is hydroxymethyl, or -CH.sub.2 NR.sub.6 R.sub.7, in which R.sub.6 is -CH.sub.2 -C.tbd.CH, -CH.sub.2 -CH=CH.sub.2, ##STR2## or alkyl of 1 to 3 carbon atoms, inclusive; R.sub.7 is hydrogen or alkyl of 1 to 3 carbon atoms, or together ##STR3## is pyrrolidino, piperidino or morpholino; wherein R.sub.2 is hydrogen, chlorine or fluorine; wherein R.sub.3 is hydrogen, or fluorine if R.sub.2 is fluorine; wherein R.sub.4 is hydrogen, fluorine, chlorine, bromine, nitro, or trifluoromethyl; and wherein R.sub.5 is hydrogen, methyl or ethyl. These compounds, except those in which R.sub.7 is hydrogen, are produced by heating a compound of formula II: ##STR4## wherein R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are defined as hereinabove, and wherein R'.sub.1 is the same as R.sub.1 except that in defining R'.sub.1,R.sub.7 may not be hydrogen, with aqueous formaldehyde in formic acid solution at reflux temperature (about 100.degree. C.).Compounds in which R.sub.7 are hydrogen require steps further shown in the specification.The compounds of formula I and their pharmacologically acceptable acid addition salts thereof have tranquilizing, anti-anxiety and anti-convulsant activity useful for the treatment of animals and man.
摘要翻译:式I的化合物:其中R 1是羟甲基或-CH 2 NR 6 R 7,其中R 6是-CH 2 -C 3 CH 3,CH 2 -CH = CH 2,或者具有1至3个碳原子的烷基,包括 ; R 7是氢或1至3个碳原子的烷基,或者一起是吡咯烷子基,哌啶子基或吗啉代; 其中R2是氢,氯或氟; 其中R 3为氢,或如果R 2为氟,则为氟; 其中R4是氢,氟,氯,溴,硝基或三氟甲基; 并且其中R 5是氢,甲基或乙基。 这些化合物除了R7是氢的化合物之外,是通过加热式II化合物制备的:其中R2,R3,R4和R5如上所定义,并且其中R'1与R1相同,除了 在定义R'1时,R7可能不是氢,甲醛水溶液在甲酸溶液中在回流温度(约100℃)下。
摘要:
Provided, among other things, is a method of treating or ameliorating or preventing an indication of the invention in an animal, including a human comprising administering an effective amount of a compound of the formula I:
摘要:
Reduction of gate-induced-drain-leakage in metal oxide semiconductor (MOS) devices is achieved by performing an anneal in a non-oxidizing ambient. In one embodiment, the anneal is performed in a argon and/or ammonia ambients after gate sidewall oxidation that forms the spacers.
摘要:
This invention pertains to a method for treating a condition of nausea and vomiting in a mammal which comprises administering a therapeutically effective amount of a 4,5,6,7-tetrahydroimidazo[4,5-c]pyridinyl-6-carboxylic acid derivative represented by the formula: ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen or lower-alkyl; R.sub.3 is selected from the group consisting of hydrogen, lower-alkyl, nitro, amino, cyano, and alkylmercapto; R.sub.4 and R.sub.5 are selected from the group consisting of hydrogen, lower-alkyl, aryl, and aryl lower-alkyl, or R.sub.4 and R.sub.5 together with the carbon atom to which they are attached form a 5- or 6-member saturated hydrocarbon ring; R.sub.6 is selected from the group consisting of hydrogen, lower-alkyl, aryl lower-alkyl, formyl, lower-alkyl carbonyl, and aryl carbonyl; R.sub.7 is selected from the group consisting of phenyl, thienyl, indolyl, indazolyl, benzo[b]furanyl, benzo[b]thiophenyl, and R.sub.8 R.sub.9 --N--; R.sub.8 is selected from the group consisting of 8-[1,2,3,4,-tetrahydroquinolinyl], pyridinyl, 3-quinolinyl, 2-naphthalinyl, 2-thiazolyl, 2-benzothiazolyl, 4-[2,1,3]benzothiadiazolyl, 2-(4,5,6,7-tetrahydrobenzo)thiazolyl, 7-(2,2-dimethyl-2,3-dihydrobenzo)furanyl, and phenyl; R.sub.9 is hydrogen or lower-alkyl; R.sub.8 R.sub.9 --N-- is selected from the group consisting of 1-indolinyl, 1-(3,3-dimethylindolinyl), and 1-(1,2,3,4-tetrahydroquinolinyl); wherein the groups represented by R.sub.7 other than R.sub.8 R.sub.9 N-- may be unsubstituted or substituted with one or more substituents selected from the group consisting of lower-alkyl, lower-alkoxy, di-lower-alkylamino, and aryloxy, and the groups represented by R.sub.8 and the radical R.sub.8 R.sub.9 N-- may have one or more substituents selected from the group consisting of hydroxy, halogen, lower-alkyl, lower-alkoxy, amino, mono- or di-lower-alkylamino, lower-alkyl carbonyl, lower-alkoxy carbonyl, and aryloxy; wherein each aryloxy group may be unsubstituted or substituted with substituents independently selected from the group consisting of lower-alkyl, lower-alkoxy, halogen, and trifluoromethyl with the proviso that, when R.sub.8 is phenyl, said phenyl group contains at least one substituent.